The FDA responds to Regeneron’s request to extend dosing intervals for Eylea HD; Regeneron applies for a new indication for Eylea HD; and several recent executive appointments are announced in the ophthalmology industry.
Learn more about your ad choices. Visit megaphone.fm/adchoices
